{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:12:03Z","timestamp":1793945523642,"version":"4.8.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10928-026-10056-5","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:15:21Z","timestamp":1785352521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["External validation of population pharmacokinetic models of adalimumab in adult patients with inflammatory bowel disease: towards model-informed precision dosing"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9431-6967","authenticated-orcid":false,"given":"Irene","family":"Aguilo-Lafarga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4974-0969","authenticated-orcid":false,"given":"Tonet","family":"Ser\u00e9s-Noriega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9066-7903","authenticated-orcid":false,"given":"Vicente","family":"Gimeno-Ballester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar Antonia","family":"Corsino Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Vicente Lidon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Maria","family":"Sierra Moros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Garcia Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Reyes","family":"Abad Sazatornil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"10056_CR1","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","volume":"74","author":"GW Moran","year":"2025","unstructured":"Moran GW, Gordon M, Sinopolou V et al (2025) British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. Gut 74:s1\u2013s101. https:\/\/doi.org\/10.1136\/gutjnl-2024-334395","journal-title":"Gut"},{"key":"10056_CR2","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","volume":"18","author":"H Gordon","year":"2024","unstructured":"Gordon H, Minozzi S, Kopylov U et al (2024) ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment. J Crohns Colitis 18:1531\u20131555. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae091","journal-title":"J Crohns Colitis"},{"key":"10056_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J et al (2022) ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis 16:2\u201317. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab178","journal-title":"J Crohns Colitis"},{"key":"10056_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.addr.2020.05.009","volume":"167","author":"M S\u00e1nchez-F\u00e9lix","year":"2020","unstructured":"S\u00e1nchez-F\u00e9lix M, Burke M, Chen HH et al (2020) Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge. Adv Drug Deliv Rev 167:66\u201377. https:\/\/doi.org\/10.1016\/j.addr.2020.05.009","journal-title":"Adv Drug Deliv Rev"},{"key":"10056_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jconrel.2018.08.001","volume":"286","author":"M Viola","year":"2018","unstructured":"Viola M, Sequeira J, Sei\u00e7a R et al (2018) Subcutaneous delivery of monoclonal antibodies: How do we get there? J Controlled Release 286:301\u2013314. https:\/\/doi.org\/10.1016\/j.jconrel.2018.08.001","journal-title":"J Controlled Release"},{"key":"10056_CR6","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1002\/jcph.374","volume":"55","author":"N Vande Casteele","year":"2015","unstructured":"Vande Casteele N, Gils A (2015) Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice. J Clin Pharmacol 55:S39\u201350. https:\/\/doi.org\/10.1002\/jcph.374","journal-title":"J Clin Pharmacol"},{"key":"10056_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cgh.2013.07.010","volume":"12","author":"X Roblin","year":"2014","unstructured":"Roblin X, Marotte H, Rinaudo M et al (2014) Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 12:80\u201384e2. https:\/\/doi.org\/10.1016\/j.cgh.2013.07.010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10056_CR8","doi-asserted-by":"publisher","first-page":"175628482513242","DOI":"10.1177\/17562848251324226","volume":"18","author":"JL Rueda Garc\u00eda","year":"2025","unstructured":"Rueda Garc\u00eda JL, Su\u00e1rez-Ferrer C, Amiama Roig C et al (2025) Association of early therapeutic drug monitoring of adalimumab with biologic remission and drug survival in Crohn\u2019s Disease. Th Adv Gastroenterol 18:17562848251324226. https:\/\/doi.org\/10.1177\/17562848251324226","journal-title":"Th Adv Gastroenterol"},{"key":"10056_CR9","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.cgh.2014.07.029","volume":"13","author":"H Yanai","year":"2015","unstructured":"Yanai H, Lichtenstein L, Assa A et al (2015) Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 13:522\u2013530e2. https:\/\/doi.org\/10.1016\/j.cgh.2014.07.029","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10056_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cgh.2015.10.025","volume":"14","author":"B Ungar","year":"2016","unstructured":"Ungar B, Levy I, Yavne Y et al (2016) Optimizing Anti-TNF-\u03b1 Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 14:550\u2013557e2. https:\/\/doi.org\/10.1016\/j.cgh.2015.10.025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10056_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","volume":"4","author":"NA Kennedy","year":"2019","unstructured":"Kennedy NA, Heap GA, Green HD et al (2019) Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 4:341\u2013353. https:\/\/doi.org\/10.1016\/S2468-1253(19)30012-3","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10056_CR12","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/apt.12940","volume":"40","author":"C Ma","year":"2014","unstructured":"Ma C, Huang V, Fedorak DK et al (2014) Adalimumab dose escalation is effective for managing secondary loss of response in Crohn\u2019s disease. Aliment Pharmacol Ther 40:1044\u20131055. https:\/\/doi.org\/10.1111\/apt.12940","journal-title":"Aliment Pharmacol Ther"},{"key":"10056_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/ibd.21328","volume":"17","author":"WJ Sandborn","year":"2011","unstructured":"Sandborn WJ, Colombel J-F, Schreiber S et al (2011) Dosage adjustment during long-term adalimumab treatment for Crohn\u2019s disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 17:141\u2013151. https:\/\/doi.org\/10.1002\/ibd.21328","journal-title":"Inflamm Bowel Dis"},{"key":"10056_CR14","doi-asserted-by":"publisher","first-page":"115421","DOI":"10.1016\/j.addr.2024.115421","volume":"215","author":"IK Minichmayr","year":"2024","unstructured":"Minichmayr IK, Dreesen E, Centanni M et al (2024) Model-informed precision dosing: State of the art and future perspectives. Adv Drug Deliv Rev 215:115421. https:\/\/doi.org\/10.1016\/j.addr.2024.115421","journal-title":"Adv Drug Deliv Rev"},{"key":"10056_CR15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/FTD.0000000000001095","volume":"45","author":"K Papamichael","year":"2023","unstructured":"Papamichael K, Stocco G, Del Ruiz A (2023) Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases. Ther Drug Monit 45:579\u2013590. https:\/\/doi.org\/10.1097\/FTD.0000000000001095","journal-title":"Ther Drug Monit"},{"key":"10056_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/pharmaceutics17040428","volume":"17","author":"SB Hanauer","year":"2025","unstructured":"Hanauer SB, Torres EA, Aragon-Han P et al (2025) The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program. Pharmaceutics 17:428. https:\/\/doi.org\/10.3390\/pharmaceutics17040428","journal-title":"Pharmaceutics"},{"key":"10056_CR17","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.14309\/ajg.0000000000001396","volume":"116","author":"AS Cheifetz","year":"2021","unstructured":"Cheifetz AS, Abreu MT, Afif W et al (2021) A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. Am J Gastroenterol 116:2014\u20132025. https:\/\/doi.org\/10.14309\/ajg.0000000000001396","journal-title":"Am J Gastroenterol"},{"key":"10056_CR18","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","volume":"17","author":"K Papamichael","year":"2019","unstructured":"Papamichael K, Cheifetz AS, Melmed GY et al (2019) Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 17:1655\u20131668e3. https:\/\/doi.org\/10.1016\/j.cgh.2019.03.037","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10056_CR19","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.gastrohep.2024.01.007","volume":"47","author":"F Rodr\u00edguez-Moranta","year":"2024","unstructured":"Rodr\u00edguez-Moranta F, Arg\u00fcelles-Arias F, Del Hinojosa J et al (2024) Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn\u2019s Disease and Ulcerative Colitis. Gastroenterol Hepatol 47:522\u2013552. https:\/\/doi.org\/10.1016\/j.gastrohep.2024.01.007","journal-title":"Gastroenterol Hepatol"},{"key":"10056_CR20","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/ecco-jcc\/jjz018","volume":"13","author":"K Papamichael","year":"2019","unstructured":"Papamichael K, Juncadella A, Wong D et al (2019) Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease. J Crohns Colitis 13:976\u2013981. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz018","journal-title":"J Crohns Colitis"},{"key":"10056_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/ftd.0000000000000494","volume":"40","author":"SE Berends","year":"2018","unstructured":"Berends SE, Mould DR, Strik AS et al (2018) Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn\u2019s Disease. Ther Drug Monit 40:202\u2013211. https:\/\/doi.org\/10.1097\/ftd.0000000000000494","journal-title":"Ther Drug Monit"},{"key":"10056_CR22","unstructured":"Food and Drug Administration (FDA) (2008) Humira: clinical pharmacology and biopharmaceutics review(s). FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/bla\/2007\/125057_S0089.pdf. Accessed 28 Nov 2025"},{"key":"10056_CR23","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.3390\/biomedicines11102822","volume":"11","author":"S Marquez-Megias","year":"2023","unstructured":"Marquez-Megias S, Nalda-Molina R, M\u00e1s-Serrano P, Ramon-Lopez A (2023) Population Pharmacokinetic Model of Adalimumab Based on Prior Information Using Real World Data. Biomedicines 11:2822. https:\/\/doi.org\/10.3390\/biomedicines11102822","journal-title":"Biomedicines"},{"key":"10056_CR24","doi-asserted-by":"publisher","first-page":"105369","DOI":"10.1016\/j.ejps.2020.105369","volume":"150","author":"JG S\u00e1nchez-Hern\u00e1ndez","year":"2020","unstructured":"S\u00e1nchez-Hern\u00e1ndez JG, P\u00e9rez-Blanco JS, Rebollo N et al (2020) Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease. Eur J Pharm Sci 150:105369. https:\/\/doi.org\/10.1016\/j.ejps.2020.105369","journal-title":"Eur J Pharm Sci"},{"key":"10056_CR25","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00228-015-1892-1","volume":"71","author":"D Ternant","year":"2015","unstructured":"Ternant D, Karmiris K, Vermeire S et al (2015) Pharmacokinetics of adalimumab in Crohn\u2019s disease. Eur J Clin Pharmacol 71:1155\u20131157. https:\/\/doi.org\/10.1007\/s00228-015-1892-1","journal-title":"Eur J Clin Pharmacol"},{"key":"10056_CR26","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/ecco-jcc\/jjz050","volume":"13","author":"N Vande Casteele","year":"2019","unstructured":"Vande Casteele N, Baert F, Bian S et al (2019) Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn\u2019s Disease: A Prospective Multicentre Study. J Crohns Colitis 13:1248\u20131256. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz050","journal-title":"J Crohns Colitis"},{"key":"10056_CR27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/BF03261932","volume":"51","author":"CMT Sherwin","year":"2012","unstructured":"Sherwin CMT, Kiang TKL, Spigarelli MG, Ensom MHH (2012) Fundamentals of population pharmacokinetic modelling: validation methods. Clin Pharmacokinet 51:573\u2013590. https:\/\/doi.org\/10.1007\/BF03261932","journal-title":"Clin Pharmacokinet"},{"key":"10056_CR28","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/jgh.16895","volume":"40","author":"K Cameron","year":"2025","unstructured":"Cameron K, Nguyen AL, Gibson DJ et al (2025) Review Article: Albumin and Its Role in Inflammatory Bowel Disease: The Old, the New, and the Future. J Gastroenterol Hepatol 40:808\u2013820. https:\/\/doi.org\/10.1111\/jgh.16895","journal-title":"J Gastroenterol Hepatol"},{"key":"10056_CR29","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","volume":"33","author":"AA Fasanmade","year":"2011","unstructured":"Fasanmade AA, Adedokun OJ, Blank M et al (2011) Pharmacokinetic properties of infliximab in children and adults with Crohn\u2019s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 33:946\u2013964. https:\/\/doi.org\/10.1016\/j.clinthera.2011.06.002","journal-title":"Clin Ther"},{"key":"10056_CR30","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/ibd\/izz192","volume":"26","author":"MJ Casanova","year":"2020","unstructured":"Casanova MJ, Chaparro M, M\u00ednguez M et al (2020) Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. Inflamm Bowel Dis 26:606\u2013616. https:\/\/doi.org\/10.1093\/ibd\/izz192","journal-title":"Inflamm Bowel Dis"},{"key":"10056_CR31","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.3390\/jcm10102132","volume":"10","author":"L Guberna","year":"2021","unstructured":"Guberna L, Nyssen OP, Chaparro M, Gisbert JP (2021) Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 10:2132. https:\/\/doi.org\/10.3390\/jcm10102132","journal-title":"J Clin Med"},{"key":"10056_CR32","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3390\/pharmaceutics13081244","volume":"13","author":"S Marquez-Megias","year":"2021","unstructured":"Marquez-Megias S, Ramon-Lopez A, M\u00e1s-Serrano P et al (2021) Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease. Pharmaceutics 13:1244. https:\/\/doi.org\/10.3390\/pharmaceutics13081244","journal-title":"Pharmaceutics"},{"key":"10056_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/00365521.2023.2278424","volume":"59","author":"SI Anjie","year":"2024","unstructured":"Anjie SI, Hanzel J, Gecse KB et al (2024) Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies. Scand J Gastroenterol 59:169\u2013175. https:\/\/doi.org\/10.1080\/00365521.2023.2278424","journal-title":"Scand J Gastroenterol"},{"key":"10056_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20524\/aog.2021.0682","volume":"35","author":"FS Fousekis","year":"2022","unstructured":"Fousekis FS, Papamichael K, Kourtis G et al (2022) The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease. Ann Gastroenterol 35:1\u20137. https:\/\/doi.org\/10.20524\/aog.2021.0682","journal-title":"Ann Gastroenterol"},{"key":"10056_CR35","doi-asserted-by":"publisher","first-page":"175628482412781","DOI":"10.1177\/17562848241278145","volume":"17","author":"P Navajas Hern\u00e1ndez","year":"2024","unstructured":"Navajas Hern\u00e1ndez P, Mouhtar El Halabi S, Gonz\u00e1lez Parra AC et al (2024) Carriage of the HLA-DQA1\u22c605 haplotype is associated with a higher risk of infratherapeutic drug concentration and higher immunogenicity in patients undergoing treatment with anti-TNF for inflammatory bowel disease. Th Adv Gastroenterol 17:17562848241278145. https:\/\/doi.org\/10.1177\/17562848241278145","journal-title":"Th Adv Gastroenterol"},{"key":"10056_CR36","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/ibd\/izad130","volume":"30","author":"A Pascual-Oliver","year":"2024","unstructured":"Pascual-Oliver A, Casas-Deza D, Cuar\u00e1n C et al (2024) HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients. Inflamm Bowel Dis 30:922\u2013929. https:\/\/doi.org\/10.1093\/ibd\/izad130","journal-title":"Inflamm Bowel Dis"},{"key":"10056_CR37","doi-asserted-by":"publisher","first-page":"jjae129","DOI":"10.1093\/ecco-jcc\/jjae129","volume":"19","author":"M Reppell","year":"2025","unstructured":"Reppell M, Zheng X, Dreher I et al (2025) HLA-DQA1*05 Associates With Anti-Tumor Necrosis Factor Immunogenicity and Low Adalimumab Trough Concentrations in Inflammatory Bowel Disease Patients From the SERENE Ulcerative Colitis and Crohn\u2019s Disease Studies. J Crohns Colitis 19:jjae129. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae129","journal-title":"J Crohns Colitis"},{"key":"10056_CR38","doi-asserted-by":"publisher","first-page":"431","DOI":"10.17235\/reed.2019.5600\/2018","volume":"111","author":"GJ Mart\u00ednez-Romero","year":"2019","unstructured":"Mart\u00ednez-Romero GJ, Alvari\u00f1o A, Hinojosa E et al (2019) Validation of a population pharmacokinetic model of adalimumab in a cohort of patients with inflammatory bowel disease. Rev Esp Enferm Dig 111:431\u2013436. https:\/\/doi.org\/10.17235\/reed.2019.5600\/2018","journal-title":"Rev Esp Enferm Dig"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10056-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-026-10056-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10056-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:21:41Z","timestamp":1792106501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-026-10056-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10056"],"URL":"https:\/\/doi.org\/10.1007\/s10928-026-10056-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8670135\/v1","asserted-by":"object"}]},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Clinical Research Ethics Committee of Autonomous Community of Aragon (CEICA) with the following registration number: EOM24\/034. The procedures established in this research are designed following the principles of good clinical practice and the declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent before enrollment in the study.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"47"}}